Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

AXL Downstream Targeting Unravels Synergistic Drug Combinations in Ovarian Carcinoma Cells.

Alampi DM, Ciusani E, Carenini N, Corna E, Gatti L, Corno C.

Anticancer Res. 2019 Jul;39(7):3803-3808. doi: 10.21873/anticanres.13529.

PMID:
31262907
2.

PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.

Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P, Gatti L.

Toxicol Appl Pharmacol. 2016 Nov 1;310:9-19. doi: 10.1016/j.taap.2016.08.005. Epub 2016 Aug 20.

PMID:
27554045
3.

Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.

Beretta GL, De Cesare M, Albano L, Magnifico A, Carenini N, Corna E, Perego P, Gatti L.

Tumori. 2016 Mar-Apr;102(2):144-9. doi: 10.5301/tj.5000471. Epub 2016 Feb 19.

PMID:
26917410
4.

Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.

Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, Perego P.

Oncotarget. 2014 Jun 30;5(12):4516-28.

5.

Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.

Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L, Corna E, Zunino F, Zaffaroni N, Perego P.

Cancer Lett. 2014 Jun 1;347(2):212-24. doi: 10.1016/j.canlet.2014.02.016. Epub 2014 Feb 24.

PMID:
24576622
6.

Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.

Gatti L, De Cesare M, Ciusani E, Corna E, Arrighetti N, Cominetti D, Belvisi L, Potenza D, Moroni E, Vasile F, Lecis D, Delia D, Castiglioni V, Scanziani E, Seneci P, Zaffaroni N, Perego P.

Mol Pharm. 2014 Jan 6;11(1):283-93. doi: 10.1021/mp4004578. Epub 2013 Nov 27.

PMID:
24256025
7.

Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.

Lecis D, De Cesare M, Perego P, Conti A, Corna E, Drago C, Seneci P, Walczak H, Colombo MP, Delia D, Sangaletti S.

Cell Death Dis. 2013 Nov 14;4:e920. doi: 10.1038/cddis.2013.449.

8.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
9.

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

Perego P, Cossa G, Tinelli S, Corna E, Carenini N, Gatti L, De Cesare M, Ciusani E, Zunino F, Luison E, Canevari S, Zaffaroni N, Beretta GL.

Biochem Pharmacol. 2012 Jan 1;83(1):27-36. doi: 10.1016/j.bcp.2011.09.021. Epub 2011 Sep 29.

PMID:
21978643
10.

Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells.

Milli A, Perego P, Beretta GL, Corvo A, Righetti PG, Carenini N, Corna E, Zuco V, Zunino F, Cecconi D.

J Proteome Res. 2011 Mar 4;10(3):1191-207. doi: 10.1021/pr100963n. Epub 2011 Jan 18.

PMID:
21142107
11.

Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards.

Pizzamiglio S, Cossa G, Gatti L, Beretta GL, Corna E, Tinelli S, Verderio P, Perego P.

Oncol Rep. 2010 Mar;23(3):853-60.

PMID:
20127029
12.

Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin.

Beretta GL, Benedetti V, Cossa G, Assaraf YG, Bram E, Gatti L, Corna E, Carenini N, Colangelo D, Howell SB, Zunino F, Perego P.

Biochem Pharmacol. 2010 Apr 15;79(8):1108-17. doi: 10.1016/j.bcp.2009.12.002. Epub 2009 Dec 31.

PMID:
20005867
13.

Novel bis-platinum complexes endowed with an improved pharmacological profile.

Gatti L, Perego P, Leone R, Apostoli P, Carenini N, Corna E, Allievi C, Bastrup U, De Munari S, Di Giovine S, Nicoli P, Grugni M, Natangelo M, Pardi G, Pezzoni G, Singer JW, Zunino F.

Mol Pharm. 2010 Feb 1;7(1):207-16. doi: 10.1021/mp900211j.

PMID:
19919086
14.

The human homolog of fission yeast Rad17 is implicated in tumor growth.

Beretta GL, Gatti L, Cesare MD, Corna E, Tinelli S, Carenini N, Zunino F, Perego P.

Cancer Lett. 2008 Aug 8;266(2):194-202. doi: 10.1016/j.canlet.2008.02.057. Epub 2008 Apr 18.

PMID:
18378394
15.

Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.

Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, Leone R, Apostoli P, Lanzi C, Zunino F.

Mol Cancer Ther. 2008 Mar;7(3):679-87. doi: 10.1158/1535-7163.MCT-07-0450.

16.

Defining targets of modulation of human tumor cell response to cisplatin.

Beretta GL, Gatti L, Corna E, Carenini N, Zunino F, Perego P.

J Inorg Biochem. 2008 Jul;102(7):1406-15. doi: 10.1016/j.jinorgbio.2008.01.002. Epub 2008 Jan 8.

PMID:
18279962
17.

Molecular alterations of cells resistant to platinum drugs: role of PKCalpha.

Righetti SC, Perego P, Carenini N, Corna E, Dal Bo L, Cedrola S, La Porta CA, Zunino F.

Biochim Biophys Acta. 2006 Jan;1763(1):93-100. Epub 2006 Jan 6.

18.

Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.

Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F.

Biochem Pharmacol. 2006 Mar 14;71(6):791-8. Epub 2006 Jan 24.

PMID:
16438941
19.

Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

Ulivi P, Zoli W, Fabbri F, Brigliadori G, Ricotti L, Tesei A, Rosetti M, De Cesare M, Beretta GL, Corna E, Supino R, Zunino F.

Neoplasia. 2005 Feb;7(2):152-61.

20.

Global gene expression of fission yeast in response to cisplatin.

Gatti L, Chen D, Beretta GL, Rustici G, Carenini N, Corna E, Colangelo D, Zunino F, Bähler J, Perego P.

Cell Mol Life Sci. 2004 Sep;61(17):2253-63.

PMID:
15338055
21.

Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.

Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, Perego P.

Biochem Pharmacol. 2004 Jul 15;68(2):283-91.

PMID:
15194000
22.

Gene expression profiles in the cellular response to a multinuclear platinum complex.

Gatti L, Beretta GL, Carenini N, Corna E, Zunino F, Perego P.

Cell Mol Life Sci. 2004 Apr;61(7-8):973-81.

PMID:
15095017
23.

Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.

Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F.

Int J Cancer. 2003 Jul 10;105(5):617-24.

24.

Single-strand conformation polymorphism for p53 mutation by a combination of neutral pH buffer and temperature gradient in capillary electrophoresis.

Gelfi C, Vigano A, De Palma S, Righetti PG, Righetti SC, Corna E, Zunino F.

Electrophoresis. 2002 May;23(10):1517-23.

PMID:
12116163
25.

Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors.

Ciusani E, Perego P, Carenini N, Corna E, Facchinetti F, Boiardi A, Salmaggi A, Zunino F.

Biochem Pharmacol. 2002 Mar 1;63(5):881-7.

PMID:
11911840
26.

Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines.

Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, Pratesi G, Supino R, Zunino F.

Curr Med Chem. 2001 Jan;8(1):31-7. Review.

PMID:
11172690
27.

Single-strand conformation polymorphism analysis by capillary zone electrophoresis in neutral pH buffer.

Gelfi C, Viganó A, Curcio M, Righetti PG, Righetti SC, Corna E, Zunino F.

Electrophoresis. 2000 Mar;21(4):785-91.

PMID:
10733223
28.

Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.

Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.

Cell Growth Differ. 1999 Jul;10(7):473-8.

Supplemental Content

Support Center